GRAIL Inc. (NASDAQ: GRAL) is a Healthcare company (Medical - Diagnostics & Research) with a market capitalization of $4.8B. The Maz Rating grades it against the other companies in its sector.
GRAIL Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $105.88, GRAIL Inc. trades at 28.6x sales and 2.0x book value. Over the last twelve months it generated about $166M of revenue and a net loss of $427M. It runs a gross margin of -13.4%, an operating margin of -347.3% and a net margin of -243.8%. It shows return on equity of -16.1%, return on invested capital of -16.2% and a free cash flow yield of -6.5%. On the balance sheet: a debt-to-equity ratio of 0.03 and a current ratio of 8.93. Over the past 52 weeks the share price ranged from $41.50 to $166.48, with a beta of 3.25.
GRAIL Inc. does not currently pay a dividend.
9 Wall Street analyst ratings cover the stock: 5 Buy and 4 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.